多管齐下 CD38 靶向增强抗 PD1 免疫检查点阻断功效。
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy.
发表日期：2024
作者：
Vishnu Vijay Vijayan, Preethi Gopalakrishnan Nair, Shashi Gujar
来源：
OncoImmunology
摘要：
CD38 是一种参与 NAD 分解代谢的多功能酶，据推测可充当抗肿瘤 CD8 T 细胞的代谢检查点。最近的一项研究发现，除了其直接代谢机制之外，CD38 介导的 RyR2-AKT-TCF1 信号传导在分子水平上调节抗 PD1 癌症治疗的反应。这些发现主张多管齐下 CD38 靶向来克服对免疫检查点阻断疗法的耐药性。© 2024 作者。经泰勒许可出版
CD38, a multifunctional enzyme involved in NAD+ catabolism, is hypothesized to act as a metabolic checkpoint for antitumor CD8 T cells. A recent study discovered that, apart from its direct metabolic mechanisms, CD38-mediated RyR2-AKT-TCF1 signaling regulates responsiveness to anti-PD1 cancer therapy at the molecular level. These findings advocate multiprong CD38 targeting to overcome resistance to immune checkpoint blockade therapy.© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.